Halozyme Therapeutics (HALO) Capital Expenditures (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Capital Expenditures data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Capital Expenditures rose 293.79% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 521.64% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 2389.29% from the prior year.
• Capital Expenditures for Q1 2026 stood at $3.7 million, up from $1.4 million in the prior quarter.
• Over the last five years, Capital Expenditures for HALO reached as high as $14.8 million in Q4 2023 and fell as low as -$7.4 million in Q4 2024.
• Historically, Capital Expenditures has averaged $1.8 million across 5 years, with a median of $1.1 million in 2022.
• On a YoY basis, Capital Expenditures climbed as much as 5957.38% in 2024 and fell as far as 1249.81% in 2024.
• Year by year, Capital Expenditures stood at $2.3 million in 2022, then jumped by 529.74% to $14.8 million in 2023, then tumbled by 149.89% to -$7.4 million in 2024, then surged by 119.38% to $1.4 million in 2025, then jumped by 162.16% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $3.7 million in Q1 2026, $1.4 million in Q4 2025, and $3.0 million in Q3 2025.